Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and another hormone, could represent a notable advancement for body treatment. Initial patient investigations have shown substantial losses in abdominal fat , potentially exceeding current weight-loss therapies . However , more study is needed to completely understand its sus